Abstract
Aspirin is not effective in the primary prevention of stroke. Patients with TIA or ischemic stroke carry a risk of recurrent stroke between 5 and 20% per year. In patients with TIA or ischemic stroke of noncardiac origin antiplatelet drugs are able to decrease the risk of stroke by 11-15% and the risk of stroke, MI and vascular death by 15-22%. Aspirin is the most widely used drug. It is affordable and effective. Low doses of 50-325 mg aspirin are as effective as high doses and cause less gastrointestinal side effects. Severe bleeding complications are dose-dependent. The combination of aspirin with slow release dipyridamole is superior to aspirin alone for stroke prevention. Clopidgrel is superior to aspirin in patients at high risk of recurrence. The combination of aspirin plus clopidogrel is not more effective than clopidogrel alone but carries a higher bleeding risk. None of the antiplatelet agents is able to reduce mortality.
Keywords: myocardial infarction, dipyridamole, Hypertension, aspirin, transient ischemic attacks
Current Pharmaceutical Design
Title: Primary and Secondary Stroke Prevention with Antiplatelet Drugs
Volume: 12 Issue: 10
Author(s): Hans-Christoph Diener
Affiliation:
Keywords: myocardial infarction, dipyridamole, Hypertension, aspirin, transient ischemic attacks
Abstract: Aspirin is not effective in the primary prevention of stroke. Patients with TIA or ischemic stroke carry a risk of recurrent stroke between 5 and 20% per year. In patients with TIA or ischemic stroke of noncardiac origin antiplatelet drugs are able to decrease the risk of stroke by 11-15% and the risk of stroke, MI and vascular death by 15-22%. Aspirin is the most widely used drug. It is affordable and effective. Low doses of 50-325 mg aspirin are as effective as high doses and cause less gastrointestinal side effects. Severe bleeding complications are dose-dependent. The combination of aspirin with slow release dipyridamole is superior to aspirin alone for stroke prevention. Clopidgrel is superior to aspirin in patients at high risk of recurrence. The combination of aspirin plus clopidogrel is not more effective than clopidogrel alone but carries a higher bleeding risk. None of the antiplatelet agents is able to reduce mortality.
Export Options
About this article
Cite this article as:
Diener Hans-Christoph, Primary and Secondary Stroke Prevention with Antiplatelet Drugs, Current Pharmaceutical Design 2006; 12 (10) . https://dx.doi.org/10.2174/138161206776361273
DOI https://dx.doi.org/10.2174/138161206776361273 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Serum Microbial- and Host-Derived Markers of Periodontal Diseases: A Review
Current Medicinal Chemistry Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives
Current Pharmaceutical Design Mechanisms for Antiplatelet Action of Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?
Current Drug Targets Medicinal Chemistry of Drugs Used in Diabetic Cardiomyopathy
Current Medicinal Chemistry Sex Hormones, Metabolic Syndrome and Kidney
Current Topics in Medicinal Chemistry Diabetic Vasculopathy and the Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1)
Current Diabetes Reviews Pentraxins: CRP and PTX3 and Cardiovascular Disease
Inflammation & Allergy - Drug Targets (Discontinued) The Effects of Psychotropic Drugs on the Regulation of Glucose Metabolism
Current Diabetes Reviews Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
Current Medicinal Chemistry Periostin as a Heterofunctional Regulator of Cardiac Development and Disease
Current Genomics From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design Development of Inhibitors of the Aspartyl Protease Renin for the Treatment of Hypertension
Current Protein & Peptide Science Benefits of Olive Oil Phenolic Compounds in Disease Prevention
Endocrine, Metabolic & Immune Disorders - Drug Targets Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets Genetic Aspects of Lone Atrial Fibrillation: What Do We Know?
Current Pharmaceutical Design Editorial [Hot Topic: Natural Products for the Healthy Heart (Guest Editor : Dipak K. Das)]
Current Pharmaceutical Biotechnology